IMMUNE RELATED ADVERSE EVENTS INDUCED BY NIVOLUMAB/IPILIMUMAB COMBINATION THERAPY NOT OBSERVED WITH NIVOLUMAB MONOTHERAPY- A STUDY OF 2 CASE REPORTS

Shrushti Dalal* and Aditya Parekh

ABSTRACT

Immune checkpoint inhibitors (ICIs) have significantly advanced cancer immunotherapy, producing substantial antitumor responses across a variety of cancer types. Combination immune checkpoint inhibitor (ICI) therapy using anti-CTLA-4 and anti-PD-1 antibodies has demonstrated superior clinical efficacy compared to monotherapy with either antibody alone.[1] However, the combination therapy is seen to be associated with an increased manifestation of autoimmune adverse effects. We present two separate patient cases in which combination therapy with Nivolumab/Ipilimumab resulted in autoimmune side effects which were not evident with Nivolumab monotherapy in the same patients.

Keywords: Immune checkpoint inhibitors, Autoimmune colitis, Autoimmune hepatitis, Monoclonal antibodies.